Adaptive, Dose-finding Phase 2 Trial Evaluating the Safety and Efficacy of ABT-089 in Mild to Moderate Alzheimer Disease

Alzheimer Disease and Associated Disorders

Volumn 29, Issue 3, 2015, Pages 192-199

  Lenz, Robert A ^a   Pritchett, Yili L ^a   Berry, Scott M ^b   Llano, Daniel A ^a   Han, Shu ^a   Berry, Donald A ^b,c   Sadowsky, Carl H ^d,e   Abi Saab, Walid M ^a   Saltarelli, Mario D ^a  

^a ABBVIE INC   (United States)

^b LLC   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d NOVA SOUTHEASTERN UNIVERSITY   (United States)

^e Premiere Res Inst P Beach Neurol   (United States)

Author keywords

adaptive trial design; Alzheimer disease; neuronal nicotinic receptor; partial agonist

Indexed keywords

DONEPEZIL; GALANTAMINE; PLACEBO; POZANICLINE; RIVASTIGMINE; CHOLINESTERASE INHIBITOR; PYRIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE;

ADULT; AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITION PORTION SCORE; ALZHEIMER DISEASE COOPERATIVE STUDY ACTIVITIES OF DAILY LIVING SCORE; ARTICLE; CAUSE OF DEATH; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; COUGHING; DISEASE SEVERITY; DIZZINESS; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SCORING SYSTEM; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; BAYES THEOREM; CLINICAL TRIAL; COGNITION; DRUG EFFECTS; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BAYES THEOREM; CHOLINESTERASE INHIBITORS; COGNITION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRIDINES; PYRROLIDINES; TREATMENT OUTCOME;

EID: 84940975714     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0000000000000093     Document Type: Article

References (34)

1. Cummings JL, Cole G. Alzheimer disease. JAMA. 2002;287: 2335-2338.
2. Gravitz L. Drugs: A tangled web of targets. Nature. 2011;475:S9-S11.
3. Gold M, Alderton C, Zvartau-Hind M, et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord. 2010;30:131-146.
4. Grove RA, Harrington CM, Mahler A, et al. A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease. Curr Alzheimer Res. 2014;11:47-58.
5. Berry DA. Bayesian clinical trials. Nat Rev. 2006;5:27-36.
6. Berry DA, Miiller P, Grieve AP, et al. Adaptive Bayesian designs for dose-ranging drug trials. In: Gatsonis C, Kass RE, Carlin B, et al, eds. Case Studies in Bayesian Statistics V. New York: Springer-Verlag; 2001:99-181.
7. Rueter LE, Anderson DJ, Briggs CA, et al. ABT-089: pharmacological properties of a neironal nicotinic acetylcho-line receptor agonist for the potential treatment of cognitive disorders. CNS Drug Rev. 2004;10:167-182.
8. Decker MW, Rueter LE, Bitner RS. Nicotinic acetylcholine receptor agonists: A potential new class of analgesics. Curr Topics Med Chem. 2004;4:369-384.
9. Gotti C, Zoli M, Clementi F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trend Pharmacol Sci. 2006;27:482-191.
10. Wang N, Orr-Urtreger A, Chapman J, et al. Autonomic function in mice lacking alpha5 neuronal nicotinic acetylcho-line receptor subunit. J Physiol. 2002;542(pt 2):347-354.
11. Wilens TE, Decker MW. Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition. Biochem Pharmacol. 2007;74:1212-1223.
12. Levin ED, McClernon FJ, Rezvani AH. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharma-cology. 2006;184:523-539.
13. Newhouse PA, Sunderland T, Tariot PN, et al. Intravenous nicotine in Alzheimer's disease: A pilot study. Psychopharma-cology. 1988;95:171-175.
14. Potter A, Corwin J, Lang J, et al. Acute effects ofthe selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease. Psychopharmacology. 1999;142:334-342.
15. World Medical Association. World Medical Association Declaration ofHelsinki: Ethical principles for medical research involving human subjects. JAMA. 2000;284:3043-3045.
16. West M, Harrison P. Bayesian Forecasting and Dynamic Models 2nd ed. New York, NY: Springer-Verlag Inc.; 1997.
17. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006;1:CD005593.
18. Berry S, Carlin B, Lee J, et al. Bayesian Adaptive Methods for Clinical Trials. Boca Raton, FL: CRC Press; 2011.
19. Padmanabhan SK, Berry S, Dragalin V, et al. A Bayesian dose-finding design adapting to efficacy and tolerability response. J Biopharm Stat. 2012;22:276-293.
20. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
21. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-1364.
22. Grottick AJ, Haman M, Wyler R, et al. Reversal ofa vigilance decrement in the aged rat by subtype-selective nicotinic ligands. Neuropsychopharmacology. 2003;28:880-887.
23. Prendergast MA, Jackson WJ, Terry AV Jr, et al. Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys. Psychophar-macology (Berl). 1998;136:50-58.
24. Chappell AS, Gonzales C, Williams J, et al. AMPA potentiator treatment of cognitive deficits in Alzheimer disease. Neurology. 2007;68:1008-1012.
25. Feldman HH, Doody RS, Kivipelto M, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010;74:956-964.
26. Green RC, Schneider LS, Amato DA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: A randomized controlled trial. JAMA. 2009;302:2557-2564.
27. Quinn JF, Raman R, Thomas RG, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: A randomized trial. JAMA. 2010;304:1903-1911.
28. Wang N, Orr-Urtreger A, Korczyn AD. The role of neuronal nicotinic acetylcholine receptor subunits in autonomic ganglia: lessons from knockout mice. Prog Neurobiol. 2002;68:341-360.
29. Mills EJ, Wu P, Lockhart I, et al. Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177, 390 individuals. Tob Induc Dis. 2010;8:8.
30. Frolich L, Ashwood T, Nilsson J, et al. Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's Disease: A phase IIb dose-finding study. J Alzheimers Dis. 2011;24:363-374.
31. Lenz RA, Garimella T, Dutta S, et al. ABT-089 demonstrates efficacy in a human model of cognition and good tolerability in subjects with Alzheimer's disease taking acetylcholinesterase inhibitors. Alzheimer Demen. 2009;5(suppl):P157.
32. Apostol G, Abi-Saab W, Kratochvil CJ, et al. Efficacy and safety of the novel alpha(4)beta(2) neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/ hyperactivity disorder: A randomized, double-blind, placebo-controlled crossover study. Psychopharmacology (Berl). 2012; 219:715-725.
33. Grottick AJ, Higgins GA. Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task. Behav Brain Res. 2000;117:197-208.
34. Howe WM, Ji J, Parikh V, et al. Enhancement of attentional performance by selective stimulation of alpha4beta2 nAChRs: underlying cholinergic mechanisms. Neuropsycho-pharmacology. 2010;35:1391-1401.